Here are three points:
1. ReActiv8 aims to provide chronic low back pain relief in adults who have attempted medical management and physical therapy.
2. The CE Mark allows Mainstay Medical to commercialize ReActiv8 in Europe.
3. Mainstay Medical will initially focus its sales and marketing efforts in Germany.
More articles on devices:
Vertebral Technologies launches pedicle screw system: 5 key notes
MiMedx to attend Craig-Hallum Institutional Investor Conference — 3 quick notes
Congress of the Chinese Association of Orthopedic Surgeons Meeting features Misonix’s BoneScalpel — 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
